Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.9% Higher – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price was up 6.9% on Monday . The stock traded as high as $8.66 and last traded at $8.34. Approximately 12,568,478 shares were traded during trading, a decline of 13% from the average daily volume of 14,385,466 shares. The stock had previously closed at $7.80.

Analyst Ratings Changes

RXRX has been the topic of a number of analyst reports. KeyCorp dropped their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $8.75.

Recursion Pharmaceuticals Stock Down 3.1 %

The firm has a market cap of $2.84 billion, a P/E ratio of -4.75 and a beta of 0.85. The firm’s 50-day moving average price is $6.91 and its 200 day moving average price is $7.02. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the prior year, the business earned ($0.43) EPS. The company’s quarterly revenue was up 147.6% on a year-over-year basis. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the completion of the sale, the director now owns 7,089,007 shares in the company, valued at $47,283,676.69. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,341 shares of company stock valued at $393,490 over the last 90 days. 15.75% of the stock is owned by company insiders.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently modified their holdings of RXRX. Allspring Global Investments Holdings LLC bought a new stake in shares of Recursion Pharmaceuticals during the third quarter valued at about $25,000. GAMMA Investing LLC raised its position in shares of Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after acquiring an additional 4,091 shares during the period. KBC Group NV boosted its holdings in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank increased its stake in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after acquiring an additional 2,459 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.